Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.7.7.6 (RNA polymerase)
 34,946 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The Inter-Company Collaboration for AIDS Drug Development (ICC) is now enrolling for its first series of clinical trials for HIV infection for patients with CD4 (T-helper) counts between 200 and 500, who have not previously taken AZT. Each 48-week trial will assign 75 volunteers to three different treatment arms. In the first trial (ICC 001), everyone will receive AZT (Retrovir) and ddC (HIVID). As the third drug, one group will receive nevirapine (an experimental non-nucleoside reverse-transcriptase inhibitor); another group will receive saquinavir (Indirase); and the third treatment group will receive the placebo. In the second trial (ICC 002), everyone will receive AZT and ddI. One group will receive nevirapine as the third drug; another group will receive 3TC as the third drug. For information on how to enroll, volunteers may call the coordinating center at PAREXEL International Corporation (800-925-AIDS). Or volunteers can call directly to the office of the physician in their city (listed in the article).
 ...
PMID:ICC Trials -- first study enrolling. 1136 34